Splenic rupture in a patient with plasma cell myeloma following G-CSF/GM-CSF administration for stem cell transplantation and review of the literature - PubMed

Review

Splenic rupture in a patient with plasma cell myeloma following G-CSF/GM-CSF administration for stem cell transplantation and review of the literature

R Veerappan et al. Bone Marrow Transplant. 2007 Aug.

Abstract

Recipients of granulocyte-colony stimulating factor/granulocyte macrophage-colony stimulating factor are not only individuals with underlying disorders, but also healthy donors undergoing peripheral blood progenitor cell (PBPC) mobilization. In addition to the known adverse effects associated with G-CSF, complications such as splenic rupture have also been reported. A review of the English literature, with addition of a patient with plasma cell myeloma, reveals that splenic rupture occurs not only in patients with underlying disease, but also in healthy PBPC donors. Although the cause of splenic rupture does not appear to be associated with any specific condition, physicians should be alerted to the possibility of this potentially fatal complication in individuals receiving G-CSF therapy.

Similar articles

• [Collection of hematopoietic progenitor cells from healthy donors].

  Bojanić I, Cepulić BG, Mazić S. Bojanić I, et al. Acta Med Croatica. 2009 Jun;63(3):237-44. Acta Med Croatica. 2009. PMID: 19827352 Review. Croatian.

• A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products.

  Lonial S, Hicks M, Rosenthal H, Langston A, Redei I, Torre C, Duenzl M, Feinstein B, Cherry J, Waller EK. Lonial S, et al. Biol Blood Marrow Transplant. 2004 Dec;10(12):848-57. doi: 10.1016/j.bbmt.2004.07.008. Biol Blood Marrow Transplant. 2004. PMID: 15570253 Clinical Trial.

• Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature.

  Jacoub JF, Suryadevara U, Pereyra V, Colón D, Fontelonga A, Mackintosh FR, Hall SW, Ascensão JL. Jacoub JF, et al. Exp Hematol. 2006 Nov;34(11):1443-50. doi: 10.1016/j.exphem.2006.06.022. Exp Hematol. 2006. PMID: 17046563 Clinical Trial.

• Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project.

  Tigue CC, McKoy JM, Evens AM, Trifilio SM, Tallman MS, Bennett CL. Tigue CC, et al. Bone Marrow Transplant. 2007 Aug;40(3):185-92. doi: 10.1038/sj.bmt.1705722. Epub 2007 Jun 11. Bone Marrow Transplant. 2007. PMID: 17563736 Review.

• Transient respiratory disturbance by granulocyte-colony-stimulating factor administration in healthy donors of allogeneic peripheral blood progenitor cell transplantation.

  Yoshida I, Matsuo K, Teshima T, Hashimoto D, Tanimoto Y, Harada M, Tanimoto M. Yoshida I, et al. Transfusion. 2006 Feb;46(2):186-92. doi: 10.1111/j.1537-2995.2006.00700.x. Transfusion. 2006. PMID: 16441593 Clinical Trial.

Cited by

• G-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use.

  Barnes G, Pathak A, Schwartzberg L. Barnes G, et al. Cancer Med. 2014 Dec;3(6):1477-84. doi: 10.1002/cam4.344. Epub 2014 Nov 20. Cancer Med. 2014. PMID: 25410813 Free PMC article. Review.

• Atraumatic idiopathic splenic rupture induced by granulocyte-colony stimulating factor (G-CSF) for the treatment of pancytopenia, managed successfully by laparoscopic splenectomy.

  Chinaka UC, Fultang J, Pereca J, Ali A. Chinaka UC, et al. BMJ Case Rep. 2020 Apr 9;13(4):e232411. doi: 10.1136/bcr-2019-232411. BMJ Case Rep. 2020. PMID: 32276997 Free PMC article.

• Colony-stimulating factors for febrile neutropenia during cancer therapy.

  Bennett CL, Djulbegovic B, Norris LB, Armitage JO. Bennett CL, et al. N Engl J Med. 2013 Mar 21;368(12):1131-9. doi: 10.1056/NEJMct1210890. N Engl J Med. 2013. PMID: 23514290 Free PMC article. Review.

• 1-Pamitoyl-2-Linoleoyl-3-Acetyl-rac-Glycerol May Reduce Incidence of Gemcitabine-Induced Neutropenia: A Pilot Case-Controlled Study.

  Oh D, Kim MH, Song TJ, Cho CJ, Nam K, Cho MK, Chun JH, Jung K, Kim KP, Kim JW. Oh D, et al. World J Oncol. 2015 Aug;6(4):410-415. doi: 10.14740/wjon937e. Epub 2015 Aug 27. World J Oncol. 2015. PMID: 28983339 Free PMC article.

• Analysis of the Safety of Pegfilgrastim Addition in Bleomycin, Etoposide, and Cisplatin Treatment Patients With Germ Cell Tumors.

  Nakagawa R, Iwamoto H, Makino T, Kadomoto S, Yaegashi H, Iijima M, Kawaguchi S, Nohara T, Shigehara K, Izumi K, Kadono Y, Mizokami A. Nakagawa R, et al. Front Oncol. 2022 Jan 7;11:770067. doi: 10.3389/fonc.2021.770067. eCollection 2021. Front Oncol. 2022. PMID: 35070973 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group
  • Ovid Technologies, Inc.

• Medical

  • MedlinePlus Health Information